News | April 28, 2026
AstraZeneca wins US nod for at-home lupus treatment in major shift for SLE care
The approval was driven by data from the Phase III TULIP-SC trial
The approval was driven by data from the Phase III TULIP-SC trial
_256_384.png)
The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs
The submission is backed by positive results from the Phase 3 AFFIRM study
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
_256_384.jpg)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
The deal signals a clear push to expand access to care in underserved regions
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c
Subscribe To Our Newsletter & Stay Updated
